Hybritech alleges patent infringement by Abbott.

San Diego-based Hybritech, a subsidiary of Eli Lilly & Co., said it has asked the U.S. District Court in Los Angeles to prohibit Chicago-based Abbott Laboratories from marketing eight testing kits that utilize monoclonal antibody technology. Hybritech alleged that the diagnostic devices, which generate 7% of Abbott’s diagnostic testing revenue, infringe upon a Hybritech patent that covers the use of monoclonal antibodies to detect medical conditions such as pregnancy, cancer and some infectious diseases.